Primary and booster meningococcal vaccination in Dutch elderly: study to investigate the immune response and determine functional antibodies after the tetravalent MenACWY-TT conjugate vaccine in the elderly population’

ational Institute for Public Health and the Environment0 个研究点目标入组 140 人开始时间: 待定最近更新: 2024年2月28日

适应症

试验速览

暂无简介。

•? Antibiotic use within 14 days of enrolment
•? Severe acute infectious illness or fever above 38.0 °C within 14 days before vaccination;
•? Present evidence of serious diseases either demanding regular use of oral immunosuppressive medical treatment, like corticosteroids, that might interfere with the results of the study within the last 3 months or demanding acute use of high dose oral immunosuppressive that might interfere with the results of the study within the last 2 weeks;
•? Known or suspected allergy to any of the vaccine components (by medical history);
•? Occurrence of a serious adverse event after other vaccination by medical history;
•? Known or suspected immune deficiency;
•? Known or suspected coagulation disorder;
•? Oral hormone use, such as postmenopausal hormones, within the last 3 months;
•? History of one of the following neurological disorders: multiple sclerosis, Parkinson’s disease, or epilepsy;
•? Previous administration of plasma-serum products including immunoglobulins within 6 months before vaccination and blood sampling;
•? Serious surgery within the last 3 months;
•? Previous vaccination with the MenC, MenC-TT or MenACWY-TT vaccine;
•? Previous confirmed or suspected meningococcal disease;
•? Any vaccination within a month before enrolment.

发起方

ational Institute for Public Health and the Environment